|
US5078996A
(en)
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
CA1341281C
(en)
|
1986-07-09 |
2001-08-07 |
Hubert J.P. Schoemaker |
Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
|
|
US5785973A
(en)
|
1988-02-01 |
1998-07-28 |
Praxis Biologics, Inc. |
Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
|
|
WO1990002806A1
(en)
|
1988-09-01 |
1990-03-22 |
Whitehead Institute For Biomedical Research |
Recombinant retroviruses with amphotropic and ecotropic host ranges
|
|
US5665577A
(en)
|
1989-02-06 |
1997-09-09 |
Dana-Farber Cancer Institute |
Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
|
|
ATE123780T1
(de)
|
1989-02-17 |
1995-06-15 |
Chiron Mimotopes Pty Ltd |
Verfahren zur verwendung und herstellung von peptiden.
|
|
JP3051411B2
(ja)
|
1989-03-14 |
2000-06-12 |
持田製薬株式会社 |
新規ｄｎａならびにそれを含有する発現プラスミド
|
|
US5266491A
(en)
|
1989-03-14 |
1993-11-30 |
Mochida Pharmaceutical Co., Ltd. |
DNA fragment and expression plasmid containing the DNA fragment
|
|
US5436146A
(en)
|
1989-09-07 |
1995-07-25 |
The Trustees Of Princeton University |
Helper-free stocks of recombinant adeno-associated virus vectors
|
|
US5976877A
(en)
|
1990-01-08 |
1999-11-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
|
|
FR2656800B1
(fr)
|
1990-01-08 |
1992-05-15 |
Roussy Inst Gustave |
Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
|
|
US7294712B2
(en)
|
1990-06-04 |
2007-11-13 |
Aventis Pharma S.A. |
Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
|
|
US5981276A
(en)
|
1990-06-20 |
1999-11-09 |
Dana-Farber Cancer Institute |
Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
|
|
CA2091346C
(en)
|
1990-09-14 |
2007-04-24 |
Philip Frost |
Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
|
|
JP3459268B2
(ja)
|
1990-09-17 |
2003-10-20 |
中外製薬株式会社 |
抗癌剤
|
|
US6596536B1
(en)
|
1991-02-08 |
2003-07-22 |
Aventis Pharma S.A. |
Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
|
|
DK0529033T3
(da)
|
1991-02-08 |
2007-01-08 |
Aventis Pharma Sa |
Nukleotidsekvenser, der koder for variable regioner af a-kæder i humane lumfocytreceptorer samt anvendelser heraf
|
|
WO1992013950A2
(fr)
|
1991-02-12 |
1992-08-20 |
Roussel-Uclaf |
SEQUENCES NUCLEOTIDIQUES CODANT POUR DES REGIONS VARIABLES DE CHAINES β DES RECEPTEURS DES LYMPHOCYTES T HUMAINS, SEGMENTS PEPTIDIQUES CORRESPONDANTS ET LES APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES
|
|
US5637483A
(en)
|
1991-10-04 |
1997-06-10 |
Whitehead Institute For Biomedical Research |
Irradiated tumor cell vaccine engineered to express GM-CSF
|
|
US5904920A
(en)
|
1991-10-04 |
1999-05-18 |
Whitehead Institute For Biomedical Research |
Regulation of systemic immune responses utilizing cytokines and antigens
|
|
US6506604B2
(en)
|
1993-06-11 |
2003-01-14 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
|
CA2189657C
(fr)
|
1994-05-06 |
2002-03-12 |
Florence Faure |
Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
|
|
US5872005A
(en)
|
1994-11-03 |
1999-02-16 |
Cell Genesys Inc. |
Packaging cell lines for adeno-associated viral vectors
|
|
JPH11507535A
(ja)
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
腫瘍の成長を抑制する抗体および抗体フラグメント類
|
|
US6040183A
(en)
|
1995-06-07 |
2000-03-21 |
University Of North Carloina At Chapel Hill |
Helper virus-free AAV production
|
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6033674A
(en)
|
1995-12-28 |
2000-03-07 |
Johns Hopkins University School Of Medicine |
Method of treating cancer with a tumor cell line having modified cytokine expression
|
|
US5840839A
(en)
|
1996-02-09 |
1998-11-24 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
|
|
US6277368B1
(en)
|
1996-07-25 |
2001-08-21 |
The Regents Of The University Of California |
Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
|
|
IL130123A
(en)
|
1996-11-28 |
2007-07-24 |
Roussy Inst Gustave |
LAG-3 protein mutants, their expression, use and method of production
|
|
PT941329E
(pt)
|
1996-11-29 |
2004-11-30 |
Applied Research Systems |
Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
|
|
US6548286B1
(en)
|
1997-04-14 |
2003-04-15 |
Cell Genesys, Inc. |
Methods for increasing the efficiency of recombinant AAV product
|
|
EP0893507A1
(en)
|
1997-07-25 |
1999-01-27 |
Institut Gustave Roussy |
Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
|
|
US6037177A
(en)
|
1997-08-08 |
2000-03-14 |
Cell Genesys, Inc. |
Method for increasing the efficiency of recombinant AAV production
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
ES2218994T3
(es)
|
1998-02-02 |
2004-11-16 |
The Johns Hopkins University School Of Medicine |
Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso.
|
|
FR2777890B1
(fr)
|
1998-04-22 |
2000-12-29 |
Roussy Inst Gustave |
Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
|
|
WO2000072686A1
(en)
|
1999-06-02 |
2000-12-07 |
Cell Genesys, Inc. |
Regulation of systemic immune responses utilizing cytokines and antigens
|
|
FR2795415B1
(fr)
|
1999-06-28 |
2003-09-05 |
Roussy Inst Gustave |
Compose peptidique derive d'une orf decalee du gene ice
|
|
AT409086B
(de)
|
1999-11-16 |
2002-05-27 |
Igeneon Krebs Immuntherapie |
Neue verwendung von antikörpern als impfstoffe
|
|
AU2001258476A1
(en)
|
2000-04-26 |
2001-11-07 |
Biovector Therapeutics |
Use of particulate vectors in immunomodulation
|
|
US7919467B2
(en)
|
2000-12-04 |
2011-04-05 |
Immunotope, Inc. |
Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
EP1295895B1
(en)
|
2001-09-19 |
2011-08-10 |
Institut Gustave Roussy |
Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
|
|
CA2752124A1
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
US7439042B2
(en)
|
2002-12-16 |
2008-10-21 |
Globeimmune, Inc. |
Yeast-based therapeutic for chronic hepatitis C infection
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
EA012066B1
(ru)
|
2003-10-10 |
2009-08-28 |
Паудерджект Вэксинс, Инк. |
Способ, вызывающий т-клеточный ответ
|
|
FR2868781B1
(fr)
|
2004-04-13 |
2008-02-22 |
Immutep |
Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
|
|
JP2006124383A
(ja)
|
2004-09-30 |
2006-05-18 |
Kobayashi Pharmaceut Co Ltd |
樹状細胞活性化剤
|
|
JP2006141346A
(ja)
|
2004-11-24 |
2006-06-08 |
Kobayashi Pharmaceut Co Ltd |
樹状細胞活性化剤
|
|
US7964571B2
(en)
*
|
2004-12-09 |
2011-06-21 |
Egen, Inc. |
Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
|
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
US20070231298A1
(en)
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
US8425897B2
(en)
|
2007-08-30 |
2013-04-23 |
Immutep S.A. |
Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AU2011339929B2
(en)
*
|
2010-12-06 |
2017-05-11 |
Tom C. Tsang |
Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
|
|
PT2691112T
(pt)
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
CA2848985A1
(en)
|
2012-02-01 |
2013-08-08 |
Compugen Ltd. |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
JP6595458B2
(ja)
|
2013-09-20 |
2019-10-23 |
ブリストル−マイヤーズ スクイブ カンパニー |
腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
|
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
WO2015131176A1
(en)
|
2014-02-28 |
2015-09-03 |
Podack Eckhard R |
Compositions, methods, and kits for treatment of cancer
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
GB201500374D0
(en)
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|